ArticleTobacco control2026
FDA authorisation of Zyn nicotine pouches: cross-sectional analysis of public discourse on X.
Article in Tobacco control, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
backgroundOn 16 January 2025, the U.S. Food and Drug Administration (FDA) authorised marketing of 20 Zyn oral nicotine pouch products, the first US authorisation of this category. Public interpretation may shape perceptions of safety and nicotine use. This study examined discourse on X following authorisation.
methodsPosts containing 'Zyn' or '#Zyn' were extracted from X from 16-23 January 2025. After excluding reposts, quote posts, non-English posts and unrelated content, 549 posts were analysed. Using an inductive approach, four coders classified posts into 10 themes and coded sentiment as supportive, opposed or neutral. Negative binomial regression models estimated associations between themes and engagement, reported as incidence rate ratios (IRRs) for views, likes, replies, reposts and quotes.
resultsMost posts were neutral (58.1%), followed by supportive (28.6%) and opposed (13.3%). The most prevalent themes were news (68.7%) and public health benefits (41.0%), followed by government distrust (16.0%) and potential harms (11.1%). Supportive posts emphasised harm reduction, whereas opposed posts highlighted regulatory distrust and concerns about addiction and youth uptake. Flavour discussion (9.5%) was strongly associated with higher engagement across metrics (all p<0.01). Posts addressing potential harms or policy inconsistencies generated lower engagement on selected metrics.
conclusionDiscourse was dominated by informational sharing and harm reduction framing, alongside regulatory scepticism. The strong association between flavour discussion and engagement indicates that flavour-related content was highly visible in the immediate X discourse surrounding the FDA authorisation. Clear communication about FDA marketing authorisation is needed to prevent misinterpretation as endorsement of safety.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.